There's also other factors.
If you don't currently hold a revenue generating product.
If you have a product that is about to have its patent elapse.
Companies looking to add to their pipeline.
There's so many factors. These drugs aren't easy to develop or have approved.
If someone wants to take a short cut they will pay more.
And with NNZ2591 looking like a platform drug someone just may want complete control so that they can take it in whatever direction they choose.
Variables all over the place. I'm going to love this Ph3.
I hope they hook into PHS now. But do we have the staff to run 2 trials?
NEU Price at posting:
$10.36 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)